Figures computed from official regulatory filings — .
Analysttarget 42.67 USD (+5233%) · consensus 4.75/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 6.46% · institutions 29.05% · short 2.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CURIS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
56 buys539 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Borgman Anne Elizabeth | AwardD (derivative) | $36K | SEC |
| Hohneker John | AwardD (derivative) | $36K | Unusual size | SEC |
| GREENACRE MARTYN Dtrack record | AwardD (derivative) | $36K | Unusual size | SEC |
| KAITIN KENNETH I | AwardD (derivative) | $36K | Unusual size | SEC |
| Dentzer James E | AwardD (derivative) | $582.4K | SEC |
| Rubin Marctrack record | AwardD (derivative) | $36K | Unusual size | SEC |
| Duvall Diantha | AwardD (derivative) | $255.4K | SEC |
| Zung Jonathan B. | AwardD (derivative) | $255.4K | SEC |
| KAITIN KENNETH I | Buy | $5.5K | conv 88First in 12mo | SEC |
| Hamdy Ahmed MDtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Zung Jonathan B. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Dentzer James E | Other | n/a (No price was disclosed in the filing) | SEC |
| Hamdy Ahmed MDtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Duvall Diantha | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Duvall Diantha | Other | n/a (No price was disclosed in the filing) | SEC |
| Zung Jonathan B. | Other | n/a (No price was disclosed in the filing) | SEC |
| Dentzer James E | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Rubin Marctrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Rubin Marctrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Duvall Diantha | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Dentzer James E | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Hamdy Ahmed MDtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Duvall Diantha | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Zung Jonathan B. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Rubin Marctrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |